Actively Recruiting
Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis
Led by Rennes University Hospital · Updated on 2023-01-18
240
Participants Needed
12
Research Sites
287 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients in maintenance treatment for HFE hemochromatosis since at least one year will be included in a two year study period and randomized in two groups experimental and control group. Because proton pump inhibitors are widely used as chronic medication, and because they can significantly modify iron absorption, patients will be stratified according to the use of proton pump inhibitors and gender. A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients. Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group (patients treated with bloodletting according to current guidelines "ferritin alone" versus patients treated with bloodletting according to "transferrin saturation and serum ferritin").Blood count and iron metabolism parameters will be performed at each bloodletting and follow-up visits. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit. Volume and schedule for bloodlettings will be determined according to guidelines specifically designed for this study to assure harmonization of treatment management, and centrally validated through the recording of the biological tests in the electronic Case Report Form which will provide the investigator with the volume and schedule of the next bloodletting. There will be two ways of treatment modification: either change of schedule or volume of bloodletting. Patients will undergo follow-up visit every six months with clinical examination, questionnaires at J0, M12 and M24 (SF-36; AIMS2-SF, WOMAC, EQ-5D-5L), and biological test. For health economics analysis, data will be obtained thanks to a dedicated extraction from SNDS database SNDS database will allow to gather hospital stays, visits, and other healthcare-related costs as well as vital status (date (month/year) of death) and cause of death. A de-identified copy of the clinical database, restricted to the relevant variables, will be sent for semideterministic matching purpose with SNDS extraction using four key variables: gender, same date (month/year) of birth, same date (day/month/year) of visit for bloodletting; pending, of course, regulatory authorization.
CONDITIONS
Official Title
Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with C282Y homozygous HFE hemochromatosis
- Completed initial treatment phase and in maintenance treatment for at least one year
- Signed informed consent form
You will not qualify if you...
- Treated with iron chelators
- Treated with erythroid growth factors (erythropoietin)
- Excessive alcohol consumption (>20g/day for women, >30g/day for men)
- Chronic hematological conditions
- Uncontrolled chronic blood loss (digestive or gynecological origin)
- Chronic kidney failure
- Diagnosis or history of cancer within the last year
- Pregnant or breastfeeding
- Enrolled in another research protocol
- Adults under legal protection or deprived of freedom
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Hopital Avicenne
Bobigny, France
Actively Recruiting
2
CHU Dupuytren
Limoges, France
Actively Recruiting
3
GHBS site du Scorff
Lorient, France
Actively Recruiting
4
GHRMSA - Hôpital Emile Muller
Mulhouse, France
Actively Recruiting
5
CHR Orléans
Orléans, France
Actively Recruiting
6
Hôpital Européen Georges Pompidou
Paris, France, 75908
Not Yet Recruiting
7
CHU Rennes
Rennes, France
Actively Recruiting
8
CH Yves le Foll
Saint-Brieuc, France
Actively Recruiting
9
CH de St Malo
St-Malo, France
Actively Recruiting
10
Hôpital Rangueil
Toulouse, France
Actively Recruiting
11
Centre hospitalier Bretagne Atlantique
Vannes, France
Actively Recruiting
12
Hôpital Paul Brousse
Villejuif, France
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here